




Belgian Cancer Registry

CANCER FACT SHEET 2023

TESTICULAR CANCER

ICD-10 C62



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with III being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Testicular cancer incidence: by region	5
1.1.1. Testicular cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Testicular cancer incidence: by tumour stage	6
1.2.2. Testicular cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	6
1.2.3. Testicular cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	6
1.2.4. Testicular cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	7
1.3. Testicular cancer incidence: by tumour type	8
1.3.5. Testicular cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.3.6. Testicular cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	8
2. CANCER INCIDENCE TRENDS	9
2.1. Testicular cancer incidence trends: by region	9
2.1.1. Testicular cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	9
2.2. Testicular cancer incidence trends: by tumour stage	11
2.2.2. Testicular cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards	11
2.3. Testicular cancer incidence trends: by age group.....	12
2.3.3. Testicular cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	12
3. CANCER PREVALENCE	13
3.1. Testicular cancer prevalence: by region	13
3.1.1. Testicular cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023.....	13
4. CANCER SURVIVAL.....	14
4.1. Testicular cancer survival: by region.....	14
4.1.1. Testicular cancer survival by region and age group: number at risk and net survival probabilities, 2014-2023	14
4.2. Testicular cancer survival: by tumour stage	16
4.2.2. Testicular cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2014-2023	16
4.2.3. Testicular cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2014-2023.....	16
4.2.4. Testicular cancer survival by stage: number at risk and net survival probabilities, 2014-2023.....	17
4.3. Testicular cancer survival: by tumour type	17

4.3.5. Testicular cancer survival by tumour type: number at risk and net survival probabilities, 2014-2023	17
5. CANCER SURVIVAL TRENDS.....	18
5.1. Testicular cancer survival trends: by tumour stage	18
5.1.1. Testicular cancer survival trends by stage: number at risk and net survival probabilities, 2004-2023	18
5.2. Testicular cancer survival trends: by tumour type	20
5.2.2. Testicular cancer survival trends by tumour type: number at risk and net survival probabilities, 2004-2023	20
6. CANCER MORTALITY	21
6.1. Testicular cancer mortality: by region	21
6.1.1. Testicular cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	21
7. CANCER MORTALITY TRENDS.....	22
7.1. Testicular cancer mortality trends: by region.....	22
7.1.1. Testicular cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	22

1. CANCER INCIDENCE



1.1. Testicular cancer incidence: by region

1.1.1. Testicular cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Belgium	0	0	2	6	39	71	87	66	62	47	27	11	8	3	2	2	0	1	1	0	435	7.6
	[0.0]	[0.0]	[0.6]	[1.8]	[11.4]	[19.5]	[22.4]	[17.6]	[16.1]	[12.6]	[6.8]	[2.7]	[2.1]	[0.9]	[0.8]	[1.0]	[0.0]	[1.3]	[3.2]	[0.0]	[7.6]	(6.9; 8.3)
Brussels	0	0	0	1	4	6	14	5	3	2	4	1	0	1	0	0	0	0	0	0	41	5.8
	[0.0]	[0.0]	[0.0]	[2.7]	[10.0]	[11.7]	[26.4]	[10.6]	[6.5]	[4.5]	[9.8]	[2.8]	[0.0]	[4.7]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.7]	(4.0; 7.6)
Flanders	0	0	2	2	19	36	43	41	32	28	14	8	4	1	0	1	0	1	1	0	233	7.2
	[0.0]	[0.0]	[1.0]	[1.0]	[10.0]	[17.8]	[19.9]	[19.4]	[14.4]	[13.3]	[6.1]	[3.3]	[1.7]	[0.5]	[0.0]	[0.8]	[0.0]	[1.9]	[4.8]	[0.0]	[7.0]	(6.3; 8.2)
Wallonia	0	0	0	3	16	29	30	20	27	17	9	2	4	1	2	1	0	0	0	0	161	9.1
	[0.0]	[0.0]	[0.0]	[2.6]	[14.1]	[26.3]	[25.1]	[17.1]	[23.1]	[14.4]	[7.2]	[1.6]	[3.4]	[1.0]	[2.3]	[1.7]	[0.0]	[0.0]	[0.0]	[0.0]	[8.9]	(7.7; 10.5)

1.2. Testicular cancer incidence: by tumour stage

1.2.2. Testicular cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages	
I	161 [11.2]	145 [12.8]	42 [1.9]	348 [6.0]	6.1 (5.5; 6.7)
II	22 [1.5]	21 [1.9]	3 [0.1]	47 [0.8]	0.8 (0.6; 1.1)
III	17 [1.2]	7 [0.6]	5 [0.2]	29 [0.5]	0.5 (0.3; 0.7)
X/NA	3 [0.2]	2 [0.2]	5 [0.2]	11 [0.2]	0.2 (0.1; 0.3)

1.2.3. Testicular cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages	
I	188 [13.1]	164 [14.5]	44 [2.0]	397 [6.9]	7.0 (6.3; 7.7)
II	8 [0.6]	4 [0.4]	4 [0.2]	16 [0.3]	0.3 (0.1; 0.4)
III	2 [0.1]	3 [0.3]	1 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
X/NA	5 [0.3]	4 [0.4]	6 [0.3]	16 [0.3]	0.3 (0.1; 0.4)

1.2.4. Testicular cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages	
I	173 [12.0]	159 [14.0]	41 [1.9]	374 [6.5]	6.6 (5.9; 7.2)
II	9 [0.6]	6 [0.5]	4 [0.2]	19 [0.3]	0.3 (0.2; 0.5)
III	18 [1.3]	8 [0.7]	5 [0.2]	31 [0.5]	0.5 (0.4; 0.7)
X/NA	3 [0.2]	2 [0.2]	5 [0.2]	11 [0.2]	0.2 (0.1; 0.3)

1.3. Testicular cancer incidence: by tumour type

1.3.5. Testicular cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Type	N[CR]				ESR2013 (95%CI)
	15-34	35-49	50+	All ages	
Seminoma	91 [6.3]	122 [10.8]	37 [1.7]	250 [4.3]	4.4 (3.9; 5.0)
Non-seminoma	108 [7.5]	48 [4.2]	10 [0.5]	167 [2.9]	2.9 (2.5; 3.3)

Note: Excluding unspecified and rare subtypes.

1.3.6. Testicular cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Sub-type	Stage	Males				
		N[CR]		ESR2013 (95%CI)		
		15-34	35-49	50+	All ages	
Seminoma	I	86 [6.0]	113 [10.0]	33 [1.5]	232 [4.0]	4.1 (3.6; 4.6)
	II	2 [0.1]	4 [0.4]	4 [0.2]	10 [0.2]	0.2 (0.1; 0.3)
	III	2 [0.1]	5 [0.4]	0 [0.0]	7 [0.1]	0.1 (0.0; 0.2)
	X/NA	1 [0.1]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
Non-seminoma	I	84 [5.8]	42 [3.7]	5 [0.2]	132 [2.3]	2.3 (1.9; 2.7)
	II	7 [0.5]	2 [0.2]	0 [0.0]	9 [0.2]	0.2 (0.1; 0.3)
	III	16 [1.1]	3 [0.3]	4 [0.2]	23 [0.4]	0.4 (0.2; 0.6)
	X/NA	1 [0.1]	1 [0.1]	1 [0.0]	3 [0.1]	0.1 (0.0; 0.1)

Note: Excluding unspecified and rare subtypes.

2. CANCER INCIDENCE TRENDS



2.1. Testicular cancer incidence trends: by region

2.1.1. Testicular cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	249	275	274	297	321	309	316	357	355	353	359	377	412	390	403	396	439	438	404	435		
	CR	4.9	5.4	5.3	5.7	6.1	5.9	5.9	6.6	6.6	6.5	6.6	6.8	7.4	7.0	7.2	7.0	7.8	7.7	7.1	7.6		
	ESR2013	4.6	5.1	5.0	5.4	5.8	5.6	5.7	6.4	6.3	6.3	6.4	6.8	7.3	6.9	7.2	7.0	7.8	7.8	7.1	7.6	2.5 (2.1; 2.9)	2004-2023
																						3.6 (2.6; 4.6)	2004-2012
																						2.7 (1.0; 4.5)	2013-2016
																					1.2 (0.0; 2.3)	2017-2023	
Brussels	N	16	20	24	21	30	29	33	27	29	20	32	28	29	32	32	38	37	51	32	41		
	CR	3.3	4.1	4.9	4.2	5.9	5.6	6.3	5.0	5.2	3.6	5.6	4.9	5.0	5.5	5.5	6.4	6.2	8.5	5.3	6.7		
	ESR2013	2.8	3.7	4.3	3.7	4.6	5.0	5.6	4.1	4.9	3.0	4.6	4.3	4.4	4.9	5.0	5.9	5.6	7.6	4.6	5.8	2.6 (1.1; 4.1)	2004-2023
Flanders	N	128	156	150	166	177	179	163	180	212	197	208	214	245	247	215	227	261	243	246	233		
	CR	4.3	5.2	5.0	5.5	5.8	5.8	5.3	5.8	6.8	6.3	6.6	6.7	7.7	7.7	6.6	7.0	8.0	7.4	7.4	7.0		
	ESR2013	4.1	5.0	4.7	5.3	5.6	5.6	5.2	5.7	6.6	6.2	6.6	6.8	7.7	7.8	6.8	7.1	8.2	7.7	7.7	7.2	2.9 (2.3; 3.4)	2004-2023
																						4.3 (3.4; 5.2)	2004-2016
																						0.5 (-1.2; 2.1)	2017-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Wallonia N	105	99	100	110	114	101	120	150	114	136	119	135	138	111	156	131	141	144	126	161		
CR	6.4	6.0	6.0	6.6	6.8	6.0	7.1	8.7	6.6	7.8	6.8	7.7	7.9	6.3	8.8	7.4	7.9	8.1	7.0	8.9		
ESR2013	6.2	5.7	5.8	6.2	6.5	5.8	6.9	8.5	6.5	7.8	6.7	7.7	7.9	6.3	8.9	7.5	7.9	8.2	7.1	9.1	1.9 (1.0; 2.7)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Testicular cancer incidence trends: by tumour stage

2.2.2. Testicular cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	328	380	369	353	374		
	CR	5.8	6.7	6.5	6.2	6.5		
	ESR2013	5.8	6.7	6.5	6.2	6.6	4.1 (3.6; 4.6)	2004-2023
							8.2 (6.3; 10.1)	2004-2010
							3.5 (1.3; 5.8)	2011-2014
							1.7 (0.7; 2.8)	2015-2023
II	N	22	19	20	17	19		
	CR	0.4	0.3	0.4	0.3	0.3		
	ESR2013	0.4	0.3	0.4	0.3	0.3	0.1 (-2.6; 3.0)	2004-2023
III	N	36	26	30	31	31		
	CR	0.6	0.5	0.5	0.5	0.5		
	ESR2013	0.6	0.5	0.5	0.5	0.5	3.2 (1.3; 5.2)	2004-2023
X/NA	N	10	14	19	3	11		
	CR	0.2	0.2	0.3	0.1	0.2		
	ESR2013	0.2	0.3	0.4	0.1	0.2	-8.7 (-12.4; -4.8)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Testicular cancer incidence trends: by age group

2.3.3. Testicular cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, %	(95%CI)	Period
15-34 N	130	155	148	164	191	174	179	195	191	190	194	199	235	202	178	188	210	216	188	203			
CR	9.7	11.6	11.1	12.3	14.2	12.9	13.2	14.2	13.8	13.7	14.0	14.3	16.9	14.5	12.8	13.4	14.9	15.3	13.2	14.1			
ESR2013	9.8	11.7	11.1	12.3	14.4	13.1	13.4	14.4	14.0	13.8	14.0	14.4	17.0	14.5	12.8	13.4	15.0	15.3	13.2	14.2	1.6 (0.8; 2.3)		2004-2023
																					5.1 (2.3; 7.9)		2004-2010
																					0.7 (-2.6; 4.1)		2011-2014
																					-0.3 (-1.9; 1.3)		2015-2023
35-49 N	89	83	95	109	101	108	92	129	123	116	137	136	126	147	179	153	164	161	160	175			
CR	7.5	7.0	7.9	9.1	8.4	9.0	7.7	10.8	10.4	9.9	11.8	11.8	11.0	12.9	15.7	13.5	14.5	14.3	14.2	15.4			
ESR2013	7.4	6.9	8.0	9.2	8.5	9.0	7.8	11.0	10.5	10.1	12.1	12.1	11.0	12.9	15.9	13.5	14.5	14.3	14.2	15.4	4.2 (3.5; 5.0)		2004-2023
50+ N	29	37	28	21	28	25	42	30	39	44	27	39	47	40	44	53	63	58	52	55			
CR	1.8	2.2	1.7	1.2	1.6	1.4	2.3	1.6	2.1	2.3	1.4	2.0	2.3	2.0	2.1	2.5	3.0	2.7	2.4	2.5			
ESR2013	1.8	2.0	1.5	1.1	1.5	1.3	2.2	1.5	1.9	2.1	1.3	1.9	2.2	1.8	2.0	2.4	2.9	2.7	2.3	2.5	3.0 (1.3; 4.7)		2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Testicular cancer prevalence: by region

3.1.1. Testicular cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		1-year	5-year	10-year	15-year	20-year
Belgium	N	425	2,013	3,775	5,225	6,386
	CR	7.3	34.7	65.1	90	110
	ESR2013	7.4	35.3	66.5	92.3	112.9
Brussels	N	41	187	316	422	503
	CR	6.7	30.5	51.6	68.9	82.2
	ESR2013	5.9	27.6	47.9	65.7	79.7
Flanders	N	228	1,162	2,203	3,027	3,668
	CR	6.8	34.4	65.2	89.6	108.6
	ESR2013	7.0	35.8	68.2	93.5	113.2
Wallonia	N	156	664	1,256	1,776	2,215
	CR	8.6	36.7	69.5	98.3	122.5
	ESR2013	8.8	37.6	71.5	101.3	126.1

4. CANCER SURVIVAL



4.1. Testicular cancer survival: by region

4.1.1. Testicular cancer survival by region and age group: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Belgium	Total	3,942	98.7% (98.3%; 99.1%)	97.8% (97.2%; 98.3%)	97.3% (96.6%; 98.0%)	95.8% (94.5%; 97.1%)
	15-34	1,970	99.5% (99.2%; 99.8%)	98.8% (98.3%; 99.3%)	98.7% (98.1%; 99.3%)	97.9% (96.7%; 99.1%)
	35-49	1,513	98.9% (98.3%; 99.5%)	98.1% (97.4%; 98.9%)	97.8% (96.9%; 98.8%)	97.2% (95.5%; 98.9%)
	50+	473	94.7% (92.5%; 97.0%)	92.4% (89.3%; 95.6%)	89.6% (85.2%; 94.2%)	82.2% (74.4%; 90.9%)
Brussels	Total	339	98.1% (96.6%; 99.7%)	96.2% (93.9%; 98.5%)	96.7% (94.4%; 99.0%)	93.5% (87.9%; 99.3%)
	15-34	169	98.9% (97.3%; 100.5%)	97.2% (94.6%; 99.8%)	97.3% (94.7%; 100.0%)	90.4% (80.8%; 101.2%)
	35-49	132	99.4% (97.9%; 100.9%)	98.9% (96.8%; 101.1%)	99.4% (97.2%; 101.5%)	98.2% (92.9%; 103.7%)
	50+	39	N<50	N<50	N<50	N<50
Flanders	Total	2,273	99.2% (98.8%; 99.6%)	99.0% (98.4%; 99.6%)	98.8% (98.1%; 99.6%)	98.1% (96.7%; 99.6%)
	15-34	1,194	99.6% (99.1%; 100.0%)	99.3% (98.8%; 99.8%)	99.3% (98.8%; 99.9%)	99.2% (98.2%; 100.2%)
	35-49	842	99.3% (98.7%; 99.9%)	98.9% (98.0%; 99.7%)	98.7% (97.6%; 99.8%)	97.2% (94.4%; 100.1%)
	50+	246	97.4% (94.9%; 100.0%)	97.9% (94.3%; 101.5%)	96.8% (91.5%; 102.3%)	95.6% (86.0%; 106.3%)
Wallonia	Total	1,331	97.9% (97.1%; 98.7%)	96.1% (94.9%; 97.3%)	94.9% (93.3%; 96.4%)	92.5% (90.1%; 95.0%)
	15-34	607	99.6% (99.0%; 100.1%)	98.2% (97.0%; 99.4%)	97.9% (96.5%; 99.2%)	97.0% (95.0%; 99.0%)
	35-49	539	98.1% (96.9%; 99.3%)	96.8% (95.2%; 98.4%)	96.2% (94.3%; 98.1%)	96.6% (94.5%; 98.8%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	50+	188	92.0% (87.9%; 96.2%)	87.3% (81.9%; 93.1%)	81.7% (74.1%; 90.0%)	67.0% (55.4%; 81.1%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2. Testicular cancer survival: by tumour stage

4.2.2. Testicular cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	3,942	98.7% (98.3%; 99.1%)	98.2% (97.8%; 98.7%)	97.8% (97.2%; 98.3%)	97.7% (97.1%; 98.3%)	97.3% (96.6%; 98.0%)	95.8% (94.6%; 97.1%)
I	3,071	99.7% (99.4%; 100.0%)	99.6% (99.3%; 99.9%)	99.3% (98.9%; 99.8%)	99.4% (98.9%; 99.9%)	99.1% (98.5%; 99.8%)	98.1% (96.9%; 99.4%)
II	505	99.2% (98.3%; 100.0%)	98.3% (97.0%; 99.5%)	98.2% (96.9%; 99.5%)	97.6% (96.1%; 99.2%)	97.2% (95.4%; 99.0%)	93.8% (89.4%; 98.4%)
III	263	89.8% (86.2%; 93.6%)	86.9% (82.8%; 91.1%)	85.3% (81.0%; 89.8%)	84.9% (80.5%; 89.5%)	84.4% (79.8%; 89.2%)	83.9% (79.1%; 89.0%)
X/NA	120	90.5% (85.1%; 96.4%)	88.7% (82.5%; 95.4%)	83.9% (76.3%; 92.2%)	82.1% (73.7%; 91.5%)	80.6% (71.7%; 90.6%)	72.8% (60.7%; 87.3%)

4.2.3. Testicular cancer survival by pathological stage (pStage): number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	3,942	98.7% (98.3%; 99.1%)	98.2% (97.8%; 98.7%)	97.8% (97.2%; 98.3%)	97.7% (97.1%; 98.3%)	97.3% (96.6%; 98.0%)	95.8% (94.6%; 97.1%)
I	3,528	99.4% (99.1%; 99.7%)	99.3% (99.0%; 99.7%)	99.2% (98.8%; 99.6%)	99.1% (98.7%; 99.6%)	98.8% (98.2%; 99.4%)	97.5% (96.2%; 98.8%)
II	157	96.9% (94.2%; 99.7%)	95.7% (92.5%; 99.1%)	94.4% (90.7%; 98.3%)	94.5% (90.8%; 98.4%)	94.7% (90.9%; 98.6%)	94.4% (90.1%; 98.9%)
III	86	93.2% (88.0%; 98.7%)	84.0% (76.5%; 92.2%)	80.3% (72.1%; 89.3%)	80.4% (72.2%; 89.5%)	80.6% (72.4%; 89.7%)	81.5% (73.2%; 90.7%)
X/NA	179	88.2% (83.4%; 93.3%)	85.9% (80.5%; 91.6%)	82.2% (76.0%; 88.9%)	80.3% (73.6%; 87.7%)	78.7% (71.5%; 86.5%)	71.9% (62.2%; 83.2%)

4.2.4. Testicular cancer survival by stage: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	3,942	98.7% (98.3%; 99.1%)	98.2% (97.8%; 98.7%)	97.8% (97.2%; 98.3%)	97.7% (97.1%; 98.3%)	97.3% (96.6%; 98.0%)	95.8% (94.6%; 97.1%)
I	3,376	99.8% (99.5%; 100.0%)	99.7% (99.4%; 100.0%)	99.5% (99.1%; 99.9%)	99.5% (99.0%; 99.9%)	99.2% (98.6%; 99.8%)	97.8% (96.5%; 99.1%)
II	166	97.8% (95.5%; 100.1%)	96.1% (93.0%; 99.2%)	94.8% (91.3%; 98.5%)	95.0% (91.5%; 98.8%)	94.3% (90.4%; 98.5%)	93.0% (87.8%; 98.5%)
III	292	90.2% (86.8%; 93.7%)	86.8% (83.0%; 90.8%)	85.4% (81.3%; 89.6%)	85.1% (80.9%; 89.4%)	84.6% (80.3%; 89.1%)	84.3% (79.8%; 89.1%)
X/NA	118	90.4% (84.8%; 96.3%)	88.5% (82.2%; 95.3%)	83.6% (75.9%; 92.1%)	81.7% (73.2%; 91.3%)	80.2% (71.2%; 90.4%)	73.7% (61.5%; 88.2%)

4.3. Testicular cancer survival: by tumour type

4.3.5. Testicular cancer survival by tumour type: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
type	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	3,942	98.7% (98.3%; 99.1%)	98.2% (97.8%; 98.7%)	97.8% (97.2%; 98.3%)	97.7% (97.1%; 98.3%)	97.3% (96.6%; 98.0%)	95.8% (94.6%; 97.1%)
Seminoma	2,149	99.4% (99.0%; 99.8%)	99.4% (98.9%; 99.8%)	99.0% (98.4%; 99.6%)	98.9% (98.3%; 99.6%)	98.8% (98.0%; 99.5%)	97.5% (96.0%; 99.0%)
Non-seminoma	1,637	97.9% (97.2%; 98.6%)	96.9% (96.0%; 97.8%)	96.6% (95.6%; 97.5%)	96.5% (95.6%; 97.5%)	96.2% (95.2%; 97.3%)	95.8% (94.3%; 97.3%)

Note: Excluding unspecified and rare subtypes.

5. CANCER SURVIVAL TRENDS



5.1. Testicular cancer survival trends: by tumour stage

5.1.1. Testicular cancer survival trends by stage: number at risk and net survival probabilities, 2004-2023

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	Total	1,377	98.7% (98.0%; 99.3%)	97.0% (96.0%; 98.0%)	96.3% (95.1%; 97.5%)
	I	995	99.4% (98.9%; 100.0%)	98.6% (97.7%; 99.5%)	98.3% (97.2%; 99.4%)
	II	93	100.2% (100.2%; 100.2%)	97.4% (93.8%; 101.0%)	96.6% (92.5%; 100.9%)
	III	90	90.1% (84.0%; 96.5%)	79.0% (70.9%; 88.0%)	74.7% (66.1%; 84.4%)
	X/NA	204	97.5% (95.2%; 99.9%)	95.9% (92.6%; 99.2%)	94.8% (91.0%; 98.7%)
2009-2013	Total	1,645	98.2% (97.6%; 98.9%)	97.1% (96.1%; 98.0%)	96.6% (95.5%; 97.7%)
	I	1,359	99.5% (99.1%; 100.0%)	98.7% (97.9%; 99.5%)	98.3% (97.3%; 99.3%)
	II	62	97.0% (92.6%; 101.5%)	95.8% (90.5%; 101.3%)	96.2% (91.0%; 101.8%)
	III	139	92.3% (87.9%; 96.8%)	88.2% (82.9%; 93.9%)	87.1% (81.5%; 93.0%)
	X/NA	89	89.3% (82.9%; 96.1%)	86.8% (79.6%; 94.7%)	85.8% (78.0%; 94.4%)
2014-2018	Total	1,890	99.0% (98.5%; 99.5%)	98.0% (97.3%; 98.8%)	97.9% (97.0%; 98.8%)
	I	1,617	100.0% (99.8%; 100.2%)	99.7% (99.2%; 100.2%)	99.8% (99.2%; 100.4%)
	II	69	97.3% (93.4%; 101.3%)	94.7% (89.4%; 100.4%)	95.2% (89.8%; 100.9%)
	III	141	90.9% (86.3%; 95.8%)	84.1% (78.2%; 90.4%)	82.9% (76.7%; 89.5%)
	X/NA	65	93.5% (87.2%; 100.3%)	90.1% (81.5%; 99.5%)	85.7% (74.9%; 98.2%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2019-2023	Total	2,072	98.4% (97.8%; 99.0%)	97.6% (96.8%; 98.4%)	96.3% (94.9%; 97.6%)
	I	1,775	99.5% (99.2%; 99.9%)	99.4% (98.8%; 99.9%)	98.0% (96.6%; 99.4%)
	II	97	98.1% (95.4%; 101.0%)	95.0% (90.3%; 99.9%)	93.0% (86.6%; 99.8%)
	III	151	89.5% (84.7%; 94.6%)	86.6% (81.2%; 92.5%)	86.9% (81.4%; 92.8%)
	X/NA	53	86.5% (77.4%; 96.8%)	75.1% (62.2%; 90.5%)	70.0% (53.8%; 91.0%)

5.2. Testicular cancer survival trends: by tumour type

5.2.2. Testicular cancer survival trends by tumour type: number at risk and net survival probabilities, 2004-2023

Period	type	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	Total	1,377	98.7% (98.0%; 99.3%)	97.0% (96.0%; 98.0%)	96.3% (95.1%; 97.5%)
	Seminoma	715	99.2% (98.4%; 99.9%)	98.2% (97.0%; 99.4%)	98.6% (97.4%; 99.9%)
	Non-seminoma	599	98.5% (97.4%; 99.5%)	95.9% (94.2%; 97.6%)	94.1% (92.0%; 96.1%)
2009-2013	Total	1,645	98.2% (97.6%; 98.9%)	97.1% (96.1%; 98.0%)	96.6% (95.5%; 97.7%)
	Seminoma	871	99.1% (98.4%; 99.8%)	98.4% (97.4%; 99.4%)	98.1% (96.8%; 99.4%)
	Non-seminoma	712	97.5% (96.3%; 98.7%)	95.7% (94.2%; 97.3%)	95.2% (93.5%; 96.9%)
2014-2018	Total	1,890	99.0% (98.5%; 99.5%)	98.0% (97.3%; 98.8%)	97.9% (97.0%; 98.8%)
	Seminoma	1,013	99.5% (99.0%; 100.0%)	99.0% (98.1%; 99.8%)	99.1% (98.2%; 100.0%)
	Non-seminoma	807	98.2% (97.3%; 99.2%)	96.7% (95.4%; 98.0%)	96.7% (95.4%; 98.1%)
2019-2023	Total	2,072	98.4% (97.8%; 99.0%)	97.6% (96.8%; 98.4%)	96.3% (94.9%; 97.6%)
	Seminoma	1,146	99.3% (98.7%; 99.8%)	99.1% (98.3%; 99.9%)	98.2% (96.9%; 99.6%)
	Non-seminoma	837	97.6% (96.6%; 98.7%)	96.5% (95.2%; 97.9%)	95.0% (92.9%; 97.2%)

Note: Excluding unspecified and rare subtypes.

6. CANCER MORTALITY



6.1. Testicular cancer mortality: by region

6.1.1. Testicular cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Belgium	0	0	0	0	0	2	2	1	2	1	0	1	1	1	2	2	0	0	1	0	16	0.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.3]	[0.5]	[0.3]	[0.0]	[0.2]	[0.3]	[0.3]	[0.8]	[1.1]	[0.0]	[0.0]	[3.6]	[0.0]	[0.3]	(0.2; 0.5)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	(0.0; 0.0)
Flanders	0	0	0	0	0	2	2	0	1	1	0	1	1	0	2	0	0	0	1	0	11	0.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[1.0]	[0.0]	[0.5]	[0.5]	[0.0]	[0.4]	[0.5]	[0.0]	[1.2]	[0.0]	[0.0]	[0.0]	[5.5]	[0.0]	[0.3]	(0.1; 0.6)
Wallonia	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	2	0	0	0	0	5	0.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.0]	[4.1]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	(0.0; 0.6)

7. CANCER MORTALITY TRENDS



7.1. Testicular cancer mortality trends: by region

7.1.1. Testicular cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	9	12	11	9	16	5	10	9	14	10	11	11	10	11	11	16	17	16		
	CR	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3		
	ESR2013	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.7 (-1.4; 2.8)	2004-2021
																				-2.6 (-6.8; 1.7)	2004-2013
																				4.6 (-0.5; 10.0)	2014-2021
Brussels	N	0	0	0	0	2	0	3	2	1	0	1	2	1	2	5	1	2	0		
	CR	0.0	0.0	0.0	0.0	0.4	0.0	0.6	0.4	0.2	0.0	0.2	0.3	0.2	0.3	0.9	0.2	0.3	0.0		
	ESR2013	0.0	0.0	0.0	0.0	0.3	0.0	0.5	0.7	0.3	0.0	0.1	0.5	0.1	0.3	0.9	0.1	0.5	0.0	NA	2004-2021
Flanders	N	5	5	5	7	9	4	5	2	5	7	3	7	4	3	3	6	8	11		
	CR	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.3		
	ESR2013	0.4	0.2	0.2	0.2	0.3	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.3	0.3	-2.7 (-6.7; 1.6)	2004-2021
																				-12.0 (-20.5; -2.6)	2004-2012
																				6.5 (-2.6; 16.3)	2013-2021
Wallonia	N	4	7	6	2	5	1	2	5	8	3	7	2	5	6	3	9	7	5		
	CR	0.2	0.4	0.4	0.1	0.3	0.1	0.1	0.3	0.5	0.2	0.4	0.1	0.3	0.3	0.2	0.5	0.4	0.3		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
ESR2013	0.2	0.4	0.4	0.1	0.3	0.1	0.2	0.3	0.5	0.2	0.7	0.1	0.3	0.4	0.2	0.5	0.4	0.3	3.1 (-2.9; 9.6)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025